Perioral Dermatitis Clinical Trial
Official title:
Laser Therapy for Perioral Dermatitis
Verified date | February 2022 |
Source | West Virginia University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Perioral dermatitis is an inflammation of the skin around the mouth. The cause of perioral dermatitis is unknown. Current treatment methods include oral antibiotics and topical calcenurin inhibitors, both of which produce side effects and have been relatively ineffective in the treatment of perioral dermatitis. The investigators hope to assess the efficacy of laser therapy in treatment of perioral dermatitis by using laser therapy on one half of the patients face and having patients apply topical medication (clindamycin) to their face for 8 weeks. The side of their face that receives laser therapy will be randomized. The investigators will assess the efficacy of laser therapy by counting the number of lesions that patients have before and after laser therapy, comparing photos of patient's perioral dermatitis before and after treatment, and having patient's rate their satisfaction of the treatment.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | June 5, 2019 |
Est. primary completion date | June 5, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - age 18 years or older - perioral dermatitis for greater than 1 month - willing to return for follow-up visits 2 weeks, 4 weeks and 8 weeks following treatment. Exclusion Criteria: - skin type V or VI (due to risk of hyperpigmentation) - pregnant - breastfeeding - unable to understand English - mentally impaired - incarcerated |
Country | Name | City | State |
---|---|---|---|
United States | West Virginia University University Town Centre Dermatology Clinic | Morgantown | West Virginia |
Lead Sponsor | Collaborator |
---|---|
West Virginia University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in number of lesions on side of the subject's face receiving laser therapy | counting number of lesions on each side of the face | initial study visit | |
Primary | Change in number of lesions on side of the subject's face receiving laser therapy | counting number of lesions on each side of the face | 4 weeks | |
Primary | Change in number of lesions on side of the subject's face receiving laser therapy | counting number of lesions on each side of the face | 8 weeks | |
Primary | Change in number of lesions on side of the subject's face receiving clindamycin alone (NO laser therapy) | counting number of lesions on each side of the face | initial study visit | |
Primary | Change in number of lesions on side of the subject's face receiving clindamycin alone (NO laser therapy) | counting number of lesions on each side of the face | 4 weeks | |
Primary | Change in number of lesions on side of the subject's face receiving clindamycin alone (NO laser therapy) | counting number of lesions on each side of the face | 8 weeks | |
Secondary | Patient opinion of side that improved more | Patients will grade satisfaction of treatment by answering "Which side of their face improved more from treatment?" with the option of responding "the right side/the left side/they are the same." | 4 weeks | |
Secondary | Patient opinion of side that improved more | Patients will grade satisfaction of treatment by answering "Which side of their face improved more from treatment?" with the option of responding "the right side/the left side/they are the same." | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00232115 -
Pimecrolimus Cream 1% in Adult Patients With Perioral Dermatitis
|
Phase 3 | |
Completed |
NCT00403949 -
A Study of Azelaic Acid (AzA) 15% in Topical Treatment of Mild to Moderate Perioral Dermatitis
|
Phase 2 | |
Completed |
NCT06461299 -
Study to Evaluate the Efficacy, Safety, and Tolerability of Sarecycline for Treating Periorificial Dermatitis
|
Phase 4 |